Document:

EX-10.11

 Exhibit 10.11 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDMENT NO. ONE TO 

ASSET PURCHASE AGREEMENT 

between: 
 CYPRESS BIOSCIENCE,
INC., 
 PROPRIUS, INC., 
 and

 EXAGEN DIAGNOSTICS 
 Dated as
of March 10, 2011 

 AMENDMENT NO. ONE TO ASSET PURCHASE AGREEMENT 

This Amendment No. One is made as of this 10th day of March, 2011 by and among Cypress Bioscience, Inc., a Delaware corporation
(“Seller”), Proprius, Inc., a Delaware corporation (“Subsidiary”), and Exagen Diagnostics, Inc., a Delaware corporation (“Purchaser” and, collectively with Seller and Subsidiary, the “Parties”) to that certain
Asset Purchase Agreement, dated as of October 8, 2010, by and among the Parties (the “Agreement”). Capitalized terms used but not defined herein shall have the respective meanings given to such terms in the Agreement. 

RECITAL 
 The Parties wish to set
forth herein amendments to certain provisions of the Agreement pertaining to the Acquired Xifin Accounts Receivable to, among other things, (a) change the amount Seller or Subsidiary is required to pay to Purchaser for the Acquired Xifin
Accounts Receivable, including for royalties and collection fees paid by Purchaser, and (b) provide that Purchaser need not collect receivables from patients except to the extent such patients have received reimbursement from insurance
companies. 
 AMENDMENT 
 The
Parties, intending to be legally bound, agree as follows: 
 1. Amendment and Restatement of Section 1.3(h). Section 1.3(h) of the
Agreement is amended and restated to read as follows: 
 “(h) Within [***] days after the delivery of each monthly
reconciliation contemplated by Section 1.8(f) of this Agreement, Seller or Subsidiary, as applicable, shall, subject to Section 10.17, pay to Purchaser: (i) for monthly reports within the period of time beginning on the Closing Date
and ending on January 31, 2011, an amount equal to (x) [***]% multiplied by all amounts received pursuant to Acquired Xifin Accounts Receivable during such month plus (y) [***]% multiplied by the amount of license royalties
paid by Purchaser under any Contracts which are attributable to such accounts receivable during such month plus (z) [***]% multiplied by the amount of the collection fee (which amount shall not exceed [***]% of the amount collected) paid
by Purchaser to Xifin with respect to such accounts receivable during such month, and (ii) for monthly reports within the period of time beginning on February 1, 2011 and continuing until the end of the Acquired Xifin Accounts Term, an
amount equal to (x) [***]% multiplied by all amounts received pursuant to Acquired Xifin Accounts Receivable during such month plus (y) [***]% multiplied by the amount of license royalties paid by Purchaser under any Contracts which
are attributable to such accounts receivable during such 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 1 

 
month plus (z) [***]% multiplied by the amount of the collection fee (which amount shall not exceed [***]% of the amount collected) paid by Purchaser to Xifin with respect to such
accounts receivable during such month. For accounts receivable for testing services performed by Purchaser with a date of service of October 6, 2010 or later (as defined by the blood sample draw date) (the “Post-10/5 Accounts
Receivable”), the Parties shall, subject to Section 10.17, follow the procedures set forth under “Post-10/5 Accounts Receivable” in Schedule 5.8.” 

2. Amendment to Section 1.7. Section 1.7 of the Agreement is amended by appending subsection (b) thereto, to read as follows: 

“(b) Notwithstanding anything to the contrary in Section 1.7(a)(iii), Purchaser shall have no obligation to make any efforts to collect
any patient receivables that are (i) [***] or (ii) [***]. For all collection efforts, Purchaser will have the right to use its patient financial assistance program and its reasonable billing and collection policies.” 

3. Treatment of Non-Xifin AR. The portion of Schedule 5.8 of the Agreement under the heading “Non-Xifin Accounts Receivable” is amended and
restated to read as follows: 
 “Non-Xifin Accounts Receivable (“Non-Xifin AR”) 

Claims or Payments for testing Services performed by Seller or Subsidiary, as applicable, with a date of service, as defined by blood sample
draw date, prior to January 12, 2010. 
  

	 	•	 	Seller will retain all rights to pursue payment for Non-Xifin AR claims. 

  

	 	•	 	Seller will not pursue payment for Non-Xifin AR resulting from amounts billed to patients if Seller or its agents have not received such Claims or Payments on or before March 10, 2011; provided, however, the
foregoing restriction shall not apply to any Reimbursement Receivables. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

	 	•	 	Purchaser will make available any information and data required to pursue Non-Xifin AR.” 

 4. Treatment
of Xifin AR. The portion of Schedule 5.8 of the Agreement under the heading “Xifin Accounts Receivable” is amended and restated to read as follows: 

“Xifin Accounts Receivable (“Xifin AR”) 

Claims and Payments for testing services performed by Seller with a date of service, as defined by the blood sample draw date, of
January 12, 2010 through the close of business on October 5, 2010: 
  

	 	•	 	All Xifin AR will be submitted for payment using Seller provider identification numbers. 

  

	 	•	 	Purchaser will work with Xifin to provide all required information for efficient processing of Xifin AR. 

  

	 	•	 	Seller will provide purchaser with electronic copies of all deposits made to Seller for Xifin AR. 

  

	 	•	 	On a monthly basis Purchaser will provide Seller with a reconciliation statement detailing the total collections by test for that month, the royalties owed on said payments, the collection fee owed to Xifin on said
payments (per the surviving contract between Purchaser and Xifin, never to exceed [***]%), the [***]% to [***]% or [***]% to [***]% split, as applicable to such month, between Seller and Purchaser of said payments and other payments owed between
Seller and Purchaser relating to the royalties and payments to Xifin. 

  

	 	•	 	Seller and Purchaser will settle the monies due within 14 days after the delivery of each monthly reconciliation statement contemplated in the previous bullet point.” 

5. Miscellaneous. Except as expressly amended hereby, the Agreement shall remain in full force and effect in accordance with the terms thereof. This
Amendment No. One will be construed in accordance with, and governed in all respects by, the laws of the State of California (without giving effect to principles of conflicts of law) and may be executed in several counterparts, each of which will
constitute an original and all of which, when taken together, will constitute one agreement. 
 [Signatures Follow] 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 The Parties have caused this Amendment No. One to be executed as of the date first written above.

  

									
	CYPRESS BIOSCIENCE, INC.	 		 	PROPRIUS, INC.
					
	By	 	 /s/ Jeffrey A. Meckler
	 		 	By	 	 /s/ Sabrina Martucci Johnson

	Name:	 	Jeffrey A. Meckler	 		 	Name:	 	Sabrina Martucci Johnson
	Title:	 	Interim Chief Executive Officer	 		 	Title:	 	President
				
	EXAGEN DIAGNOSTICS, INC.	 		 		 	
					
	By	 	 /s/ Scott L. Glenn
	 		 		 	
	Name:	 	Scott L. Glenn	 		 		 	
	Title:	 	Chairman and Chief Executive Officer	 		 		 	

  
 [Signature page to
Amendment No. One]EX-10.15

 Exhibit 10.15 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

 This Agreement is made and entered into as of the 2nd day of
August, 2011 (“EFFECTIVE DATE”), by and between the UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with
an office at 200 Gardner Steel Conference Center, Thackeray and O’Hara Streets, Pittsburgh, Pennsylvania 15260 (“UNIVERSITY”), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an
office at 801 University Blvd. SE Suite 103 Albuquerque, NM 87106 (“LICENSEE”). 
 WHEREAS, UNIVERSITY is the owner by assignment
from the inventors of certain PATENT RIGHTS, entitled “Diagnosis and Monitoring of Systemic Lupus Erythematosus,” developed by Drs. Susan Manzi and Joseph Ahearn of the UNIVERSITY faculty, consisting of certain patents and patent
applications, and the UNIVERSITY has the right to grant licenses under such PATENT RIGHTS; 
 WHEREAS, UNIVERSITY desires to have the PATENT
RIGHTS utilized in the public interest; 
 WHEREAS, LICENSEE has represented to UNIVERSITY, to induce UNIVERSITY to enter into this
Agreement, that LICENSEE is experienced in the development, production, manufacture, marketing and sale of products and/or the use of similar products to the LICENSED TECHNOLOGY and that LICENSEE shall commit itself to a thorough, vigorous and
diligent program of exploiting the PATENT RIGHTS so that public utilization results therefrom; 
 WHEREAS, UNIVERSITY and CYPRESS
BIOSCIENCE, INC., as successor in interest to CELLATOPE CORPORATION (formerly STAGEMARK, INC.), entered into an Exclusive License Agreement dated as of October 11, 2005, as amended by a First Amendment to Exclusive License Agreement dated
May 25, 2006, a Second Amendment to Exclusive License Agreement on February 21, 2007, a Third Amendment to Exclusive License Agreement on February 23, 2009, and a Fourth Amendment to Exclusive License Agreement on September 21,
2010; 

  
 1 

 WHEREAS, CYPRESS BIOSCIENCE, INC. assigned the Exclusive License Agreement, as amended, to EXAGEN
DIAGNOSTICS, INC., by an Assignment and Assumption Agreement dated October 16, 2010; and 
 WHEREAS, LICENSEE desires to amend and
restate in its entirety the Exclusive License Agreement, as amended, and to obtain a license under the PATENT RIGHTS upon the terms and conditions hereinafter set forth. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto, intending to be legally bound,
agree as follows: 
 ARTICLE I - DEFINITIONS 

For purposes of this Agreement, the following words and phrases shall have the following meanings: 

 

	1.1	“AFFILIATE” shall mean, with respect to the UNIVERSITY, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by UNIVERSITY.

  

	1.2	“COMMERCIALLY REASONABLE BEST EFFORTS” shall mean, with respect to the research, development and commercialization of any product, compound or process, the level of efforts and resources used by [***]

  

	1.3	“LICENSEE” shall mean Exagen Diagnostics, Inc. and all entities at least fifty percent (50%) owned or controlled by Exagen Diagnostics, Inc. 

 

	1.4	“LICENSED TECHNOLOGY” shall mean any product or part thereof or service which is: 

  

	 	(a)	Covered in whole or in part by an issued, unexpired or pending claim contained in the PATENT RIGHTS in the country in which any such product or part thereof is made, used or sold or in which any such service is used or
sold; and 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

	 	(b)	Manufactured by using a process or is employed to practice a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the PATENT RIGHTS in the country in which any such
process in the SLE FIELD is used or in which such product or part thereof or service is used or sold. 

  

	1.5	“NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES” shall mean use of PATENT RIGHTS (including distribution of biological materials covered by the PATENT RIGHTS) for academic research or other not-for-profit
scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the PATENT RIGHTS in the production or manufacture of products for sale or the performance of services for a fee. 

 

	1.6	“NON-ROYALTY SUBLICENSE INCOME” shall mean [***] pursuant to any sublicense granted pursuant to Section 2.3 hereunder, provided however, that NON ROYALTY SUBLICENSE INCOME does not include any [***].

  

	1.7	“PATENT RIGHTS” shall mean UNIVERSITY intellectual property described below and assigned to the UNIVERSITY: 

  

	 	(a)	The United States and foreign patents and/or patent applications listed in Exhibit A; 

  

	 	(b)	United States and foreign patents issued from the applications listed in Exhibit A and from divisionals and continuations and continuations in part of these applications; and 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

	 	(c)	Claims of U.S. and foreign continuation in part and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed in
Exhibit A. 

 For the avoidance of doubt, PATENT RIGHTS specifically excludes the patents and/or patent applications listed in
Exhibit B and any U.S. and foreign patents issued therefrom and any divisionals, continuations, and continuations in part of these applications. 
  

	1.8	“NET SALES” shall mean gross invoice price actually charged by LICENSEE or its Sublicensee to third parties for LICENSED TECHNOLOGY and services or testing using the LICENSED TECHNOLOGY and services, less the
following deductions where they are factually applicable and are not already reflected in the gross invoice price: 

  

	 	(a)	Actual cost of freight, shipping and insurance charges or freight absorption, separately stated in such invoice; 

  

	 	(b)	Actual trade, quantity or cash discounts actually allowed, to include discounts to managed care organizations, so long as such discounts: (i) are in amounts customary in the trade, and (ii) do not violate
federal state laws or regulations; 

  

	 	(c)	Actual credits and allowances granted for product returns, rejection for damages and recalls; 

  

	 	(d)	Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid, Medicare or similar state and federal government programs; and 

 

	 	(e)	Sales taxes, tariff duties and/or use taxes actually paid and separately stated on each invoice. 

  

	1.9	“SLE FIELD” shall mean any and all applications of the Patent Rights in Systemic Lupus Erythematosus. 

  

	1.10	“TERRITORY” shall mean worldwide. 

 ARTICLE 2 – GRANT 

  
 4 

	2.1	Subject to the terms and conditions of this Agreement, UNIVERSITY hereby grants to LICENSEE, to the extent it may lawfully do so, the right and exclusive license in the TERRITORY to make, have made, use, offer for sale,
import and sell the LICENSED TECHNOLOGY in the SLE FIELD and to practice under the PATENT RIGHTS in the SLE FIELD to the end of the term for which the PATENT RIGHTS are granted, unless this Agreement is terminated as provided herein. UNIVERSITY
reserves the royalty-free, nonexclusive right to practice under the PATENT RIGHTS for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES and to use the LICENSED TECHNOLOGY for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES. 

 

	2.2	The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. §200, et seq. Pursuant to this law, the United States government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the PATENT RIGHTS throughout the world. Pursuant to 35 U.S.C. §200, el seq. LICENSED TECHNOLOGY
produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. §204 is granted by the appropriate United States government agencies). 

 

	2.3	LICENSEE shall have the right to enter into sublicensing arrangements (without the right for further sublicense) for the rights, privileges and licenses granted hereunder. Prior written approval of each sublicensee by
UNIVERSITY which approval shall not be unreasonable withheld or delayed, will be required for all sublicensees, except in such cases where the sublicense: (1) has at least one FDA approved medical diagnostic test currently on the market: and
(2) has yearly revenues from the commercial sale of diagnostic products in excess of [***] dollars ($[***]). Upon termination of this Agreement, rights of any sublicensee granted by Licensee pursuant to this Section 2.3 shall survive such
termination at the written request of such sublicensees provided to UNIVERSITY, provided that the action or inaction of such sublicense was not the cause of such termination. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 5 

	2.4	LICENSEE agrees that any sublicense granted by it shall provide that the obligations to UNIVERSITY of Articles 2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this
Agreement. Each sublicense granted by LICENSEE pursuant to this Agreement shall include an audit right by UNIVERSITY of sublicensee of the same scope as provided in Section 5.2 with respect to LICENSEE. 

 

	2.5	LICENSEE agrees to forward to UNIVERSITY a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30) days after each such sublicense agreement has been
executed by both parties thereto. 

  

	2.6	The license granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology other than PATENT RIGHTS. 

ARTICLE 3 - DUE DILIGENCE 
  

	3.1	LICENSEE shall use its [***] to bring the LICENSED TECHNOLOGY to market as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts for
the LICENSED TECHNOLOGY throughout the term of this Agreement. 

  

	3.2	In addition, LICENSEE shall adhere to each of the following milestones in the SLE FIELD: 

 (a)
Within twelve (12) months from the Effective Date of this Agreement, the sale or offer for sale of at least one (1) test system with clinical utility, diagnosis or monitoring, in Systemic Lupus Erythematosus; 

(b) Within twenty four months (24) from the Effective Date of this Agreement, begin clinical trials for monitoring claims; and 

(c) Within twenty four months (24) from the Effective Date of this Agreement, seek expansion of use of the Licensed Technology outside the
United States. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 6 

	3.3	LICENSEE’s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis anyone of the milestones set forth in Section 3.2 hereof shall be grounds for UNIVERSITY to terminate this
Agreement pursuant to Section 10.2(a); except that for a single time, if a milestone in Section 3.2 has not been completed within the time frame allotted through no fault of LICENSEE and following the best efforts of LICENSEE to meet such
milestone, LICENSEE may, on a one-time basis, notify the UNIVERSITY in writing that it desires a single six (6) month extension to meet such milestone and LICENSEE shall be deemed to have fulfilled the milestone requirement if LICENSEE makes a
penalty payment of [***] dollars ($[***]) with both notice and penalty payment to be received by the UNIVERSITY within ten days of the applicable milestone achievement date. In such case the LICENSEE and UNIVERSITY shall negotiate a new time for
attainment of such missed milestone (not to exceed six months) and subsequent timeframes relying upon the meeting of previous milestones may also be adjusted. If LICENSEE fails to meet any revised milestone including first missed milestone,
UNIVERSITY may terminate the License and upon termination all rights and interest to the PATENT RIGHTS and any other rights granted by UNIVERSITY shall revert to UNIVERSITY. 

ARTICLE 4 - LICENSE CONSIDERATION 
  

	4.1	In consideration of the rights, privileges and license granted by UNIVERSITY hereunder, LICENSEE shall pay royalties and other monetary consideration as follows:; 

 

	 	(a)	Annual maintenance fees, non-refundable and non-creditable against royalties, until the first NET SALES occur as follows: 

  

	 	(i)	[***] Dollars ($[***]) on the first and second anniversary of the EFFECTIVE DATE of this Agreement; and 

  

	 	(ii)	[***] Dollars ($[***]) on the third anniversary of the EFFECTIVE DATE of this Agreement and annually thereafter until the first NET SALES. 

Upon the first NET SALES, no further maintenance fees shall be due hereunder. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 7 

	 	(b)	Royalties in an amount equal to [***] Percent ([***]%) of NET SALES of the LICENSED TECHNOLOGY per calendar quarter and royalties in an amount equal to [***] Percent ([***]%) of sublicensee NET SALES per calendar
quarter; 

  

	 	(c)	Beginning with the first NET SALES, a minimum royalty in the following amounts, if such minimum royalty is greater than the aggregate annual royalty computed in accordance with Section 4.1(b) above:

  

	 	(i)	[***] Dollars ($[***]) per calendar year for the first calendar year of the first NET SALES; 

  

	 	(ii)	[***] Dollars ($[***]) per calendar year for the second calendar year of the first NET SALES; and 

  

	 	(iii)	[***] Dollars ($[***]) in each subsequent calendar year during the term of this Agreement. 

  

	 	(d)	Milestone payments shall be paid by LICENSEE to UNIVERSITY as follows: 

  

	 	(i)	Two Hundred Thousand Dollars ($200,000) payable within [***] days following [***] NET SALES in a calendar year. 

  

	 	(e)	A share of NON-ROYALTY SUBLICENSE INCOME of [***] Percent ([***]%). 

  

	4.2	In the event that it should prove necessary for LICENSEE to license intellectual property rights owned by a third party in order to practice the LICENSED TECHNOLOGY in the SLE FIELD in order to avoid infringing the
patent or other intellectual property rights of such third party, then LICENSEE shall be entitled to a credit of such third party royalties against royalties due to UNIVERSITY under Section 4.1(b), and Section 4.1(c), provided that
(i) in no event shall the royalty rate applicable to NET SALES in the SLE FIELD be less than [***] percent ([***]%) and (ii) in no event shall the royalty rate applicable to NET SALES in the SLE FIELD from a sub-Licensee be less than [***]
percent ([***]%). 

  

	4.3	 All payments pursuant to this Agreement may be made by check or by wire transfer (along with applicable wire transfer fees) in United States dollars
without deduction or exchange, collection or other charges and directed to the address or , in the case of wire 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 8 

	 	
transfer, to the bank, set forth in Article II. Annual maintenance payments pursuant to Section 4.1(a) hereof shall be paid on the anniversary of the EFFECTIVE DATE of the calendar year in
which they are due. Royalty payments pursuant to Section 4.1 (b) hereof shall be due within thirty (30) days after each March 31, June 30, September 30 and December 31. The minimum annual royalty for any
calendar year pursuant to Section 4.1(c) shall be paid by January 30 of the subsequent calendar year. NONROYALTYSUBLICENSE INCOME payments pursuant to Section 4.1(e) hereof shall be paid within thirty (30) days after receipt of
payment by LICENSEE from sublicense. Payments under Section 4.1(b) are payable on a country by country basis only in those countries in which there are PATENT RIGHTS with respect to the applicable LICENSED TECHNOLOGY. 

 

	4.4	Taxes imposed by any foreign or United States governmental agency on any payments to be made to the UNIVERSITY by LICENSEE hereunder shall be paid by LICENSEE without deduction from any payment due to the UNIVERSITY
hereunder. 

  

	4.5	Payments pursuant to this Agreement, including those specified in Section 6.2, which are overdue shall bear interest calculated from the due date until payment is received at the rate of five percent (5%) per
annum, or the prime rate (as quoted by The Wall Street Journal) plus two percent (2%), whichever is higher. Payment of such interest by LICENSEE shall not negate or waive the right of UNIVERSITY to seek any other remedy, legal or equitable, to which
it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. 

  

	4.6	LICENSEE shall sell products and/or processes resulting from LICENSED TECHNOLOGY to UNIVERSITY and its AFFILIATES upon request at such price(s) and on such terms and conditions as such products and/or processes are made
available to LICENSEE’S most favored customer. 

 ARTICLE 5 - REPORTS 

 

	5.1	 Within sixty (60) days after each March 31, June 30, September 30 and December 31 of each year during the term of
this Agreement beginning in the year of the first commercial 

  
 9 

	 	
sale of LICENSED TECHNOLOGY, LICENSEE shall deliver to UNIVERSITY true, accurate and detailed reports of : 

  

	 	(a)	Number of product and service NET SALES, each stated separately, for LICENSEE and all sublicensees; 

  

	 	(b)	Total billings and receivables for all such products and services; 

  

	 	(c)	Deductions set forth in Section 1.8, each stated separately; 

  

	 	(d)	Total royalties due; 

  

	 	(e)	Name and addresses of sublicensees; and 

  

	 	(f)	Total NON-ROYALTY SUBLICENSE INCOME received during such calendar quarter and total amount of payment due pursuant to Section 4.1(e). 

 

	5.2	LICENSEE shall keep full, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable
to UNIVERSITY hereunder. Such books of account shall be kept at LICENSEE’s principal place of business. Such books and the supporting data related thereto shall be made available at reasonable times for no more than once a calendar year for
[***] years following the end of the calendar year to which they pertain to the inspection of UNIVERSITY or its agents for the purpose of verifying LICENSEE’S royalty statement or compliance in other respects with this Agreement. The fees and
expenses of UNIVERSITY’S representatives shall be borne by UNIVERSITY; however, if an error of more than the greater of [***] percent ([***]%) of the total payments or the cost of such an audit due or owing for any year is discovered, then
LICENSEE shall bear the fees and expenses of UNIVERSITY’S representatives. 

  

	5.3	 No later than ninety (90) days after December 31 of each calendar year during the term of this Agreement, LICENSEE shall provide to
UNIVERSITY a written annual progress report, describing LICENSEE’S progress on market introduction and milestones relating 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 10 

	 	
to the LICENSED TECHNOLOGY during the preceding twelve month period ending December 31. 

ARTICLE 6 -PATENT PROSECUTION 
  

	6.1	UNIVERSITY has or shall apply for and seek prompt issuance of and maintain during the term of this Agreement the PATENT RIGHTS in the United States and in such foreign countries as may be designated by LICENSEE in a
written notice to UNIVERSITY within a reasonable time in advance of the required foreign filing dates. LICENSEE shall have the opportunity to advise and cooperate with UNIVERSITY in the prosecution, filing and maintenance of such patents. If
UNIVERSITY decides to abandon the preparation, filing, prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then UNIVERSITY shall provide written notice to LICENSEE, and LICENSEE shall have the right at its
sole expense to assume control of the preparation, filing, prosecution and maintenance of such patent application or patent. If LICENSEE no longer wishes to support the prosecution or maintenance of any patent or patent application covered by the
PATENT RIGHTS, then LICENSEE shall provide written notice to UNIVERSITY, and LICENSEE shall not be responsible for such corresponding patent expenses that are incurred subsequent to the date of receipt by UNIVERSITY of such written notice by
LICENSEE; such returned patent or patent application shall be excluded from the PATENT RIGHTS. LICENSEE shall notify UNIVERSITY immediately if, at any time during the term of this Agreement, LICENSEE or any of its sublicensees does not qualify as a
“Small Entity” as provided by the United States Patent and Trademark Office. 

  

	6.2	All fees and costs including attorneys’ fees relating to the filing, prosecution and maintenance of the PATENT RIGHTS whether incurred prior to or after the EFFECTIVE DATE of this Agreement shall be the
responsibility of LICENSEE. LICENSEE shall not be required to reimburse the UNIVERSITY for any fees under this section that have been paid to the UNIVERSITY by prior licensees or any other third party. Fees and costs shall be paid by LICENSEE within
thirty (30) days after receipt of UNIVERSITY’S invoice therefore. Payments pursuant to this Section 6.2 are not creditable against royalties. 

  
 11 

	6.3	LICENSEE shall own any new patent application, and any patent that issues therefrom, or new technology in the SLE FIELD developed independently of the UNIVERSITY and UNIVERSITY employees and shall not owe the UNIVERSITY
any fee or royalty under section 4 relating to such a new patent application, and any patent that issues therefrom, or new technology. 

ARTICLE 7 -INFRINGEMENT ACTIONS 
  

	7.1	LICENSEE shall inform UNIVERSITY promptly in writing of any alleged infringement of the PATENT RIGHTS by a third party and of any available evidence thereof. 

 

	7.2	During the term of this Agreement, LICENSEE shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the PATENT RIGHTS in the Field if LICENSEE has notified UNIVERSITY in
writing of its intent to prosecute. In furtherance of such right, UNIVERSITY hereby agrees that LICENSEE may include UNIVERSITY as a party plaintiff in any such suit, without expense to UNIVERSITY. [***] 

 

	7.3	If within six (6) months after having been notified of any alleged infringement, LICENSEE shall have been unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be
diligently prosecuting an infringement action, or if LICENSEE shall notify UNIVERSITY at any time prior thereto of its intention not to bring suit against any alleged infringer, then, and in those events only, UNIVERSITY shall have the right, but
shall not be obligated, to prosecute at its own expense any infringement of the PATENT RIGHTS, and UNIVERSITY may, for such purposes, use the name of LICENSEE as party plaintiff. [***] 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 12 

 [***] 
  

	7.4	In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS shall be brought against UNIVERSITY, LICENSEE, at its option, shall have the right, within thirty
(30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. 

  

	7.5	In any infringement suit either party may institute to enforce the PATENT RIGHTS pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects
and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like. 

ARTICLE 8 -INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY 
  

	8.1	LICENSEE shall at all times during the term of this Agreement and thereafter indemnify, defend and hold UNIVERSITY, its trustees, officers, faculty member, employees and Affiliates (“INDEMNIFIED PARTIES”)
harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of the death of or injury to any person or persons or out of any damage to property or the environment, and against any other claim,
proceeding, demand, expense and liability of any kind whatsoever resulting from: (i) the production, manufacture, sale, use, lease, consumption or advertisement of the LICENSED TECHNOLOGY by Licensee to its sublicensees, (ii) the practice
by LICENSEE or any Affiliate or sublicensee of the PATENT RIGHTS; or (iii) arising from or relating to this License Agreement. LICENSEE shall provide this defense and indemnity whether or not any INDEMNIFIED PARTIES, either jointly or
severally, is named as a party defendant and whether or not any INDEMNIFIED PARTIES is alleged to be negligent or otherwise responsible for any injuries to person or property. The obligation of LICENSEE to defend and indemnify as set forth herein
shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

	8.2	LICENSEE shall obtain and carry in full force and effect liability insurance which shall protect LICENSEE and UNIVERSITY in regard to events covered by Section 8.1 above, as provided below: 

 

					
	 	 	 COVERAGE
	 	 LIMITS

			
	 (a)
	 	Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury	 	$1,000,000 Combined Single Limits for Bodily Injury and Property Damage
			
	 (b)
	 	Products Liability	 	$5,000,000

 The UNIVERSITY of Pittsburgh is to be named as an additional insured with respect to insurance policies
identified in Sections 8.2(a) and 8.2Cb) above. Certificates of insurance evidencing the coverage required above shall be filed with the UNIVERSITY’S Office of Technology Management, 200 Gardner Steel Conference Center, Pittsburgh, PA 15260, no
later than fifteen (15) days after execution of this Agreement and annually thereafter. Such certificates shall provide that the insurer will give the UNIVERSITY not less than thirty (30) days advance written notice of any material changes
in or cancellation of coverage. 
  

	8.3	 UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT
NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF
THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES, FOR DAMAGES, INCLUDING, BUT NOT LIMITED
TO, DIRECT, 

  
 14 

	 	
INDIRECT, SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS),
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT OR
SERVICE THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER. 

ARTICLE 9 - ASSIGNMENT 

Except as expressly provided hereunder, this Agreement is not assignable without the prior written consent of UNIVERSITY which consent shall
not be unreasonably withheld, and any attempt to do so shall be null and void, provided that LICENSEE may assign this Agreement and its rights and obligations thereunder, without the UNIVERSITY’S prior written consent in connection with the
transfer or sale of all or substantially all of the LICENSEE’S business relating to the PATENT RIGHTS and LICENSED TECHNOLOGY to a third party, whether by merger, sale of stock, sale of assets or otherwise subject to LICENSEE providing at least
10 business days written notification to UNIVERSITY and further subject to the assignee agreeing writing to be bound to all the terms and conditions of this License. The rights and obligations of the parties under this Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Article 9 shall be null and void. 

ARTICLE 10 - TERMINATION 
  

	10.1	This Agreement shall terminate upon the expiration of the last surviving claim of the PATENT RIGHTS. 

  

	10.2	UNIVERSITY shall have the right to terminate this Agreement if: 

  
 15 

	 	(a)	LICENSEE shall default in the performance of any of the obligations herein contained and such default has not been cured within [***] days after receiving written notice thereof from UNIVERSITY; or 

 

	 	(b)	LICENSEE shall cease to carry out its business, become bankrupt or insolvent, apply for or consent to the appointment of a trustee, receiver or liquidator of its assets or seek relief under any law for the aid of
debtors. 

  

	10.3	LICENSEE may terminate this Agreement upon six (6) months prior written notice to UNIVERSITY and payment of all amounts due UNIVERSITY through the effective date of termination, including patent cost reimbursement
pursuant to Article 6 hereof. 

  

	10.4	Upon termination of this Agreement, neither party shall be released from any obligation that matured prior to the effective date of such termination. LICENSEE and any sublicensee may, however, after the effective date
of such termination, sell all products under the LICENSED TECHNOLOGY which LICENSEE produced prior to the effective date of such termination, provided that LICENSEE shall pay to UNIVERSITY the royalties thereon as required by Article 4 hereof and
submit the reports required by Article 5 hereof. 

 ARTICLE 11 - NOTICES 

 

	11.1	Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed
to the address below or as either party shall designate by written notice to the other party. 

 In the case of UNIVERSITY:

 Director 
 Office of
Technology Management 
 University of Pittsburgh 

200 Gardner Steel Conference Center 

Thackeray & O’Hara Streets 

Pittsburgh, PA 15260 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 16 

 In the case of LICENSEE: 

Exagen Diagnostics, Inc. 
 801
University Blvd SE 
 Suite 103 

Albuquerque, NM 87106 
 Attn:
President 
  

	11.2	Any payments to UNIVERSITY hereunder by wire transfer shall be directed as follows: 

 Bank:
Mellon Bank, NA, Pittsburgh, PA 
 ABA Routing No.: 043000261-UNIVERSITY of Pittsburgh 

Account No.: 0015510 
 Mellon
SWIFT Code: MELNUS3P (international transfers) 
 Reference Code: Office of Technology Management 

ARTICLE 12 - AMENDMENT, MODIFICATION 
  

	12.1	This Agreement may not be amended or modified except by the execution of a written instrument signed by the parties hereto. 

ARTICLE 13 - MISCELLANEOUS 
  

	13.1	This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals, such
as University employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United States District Court for the Western District of Pennsylvania. 

 

	13.2	The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or
understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement. 

  

	13.3	 Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional
activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of the other party, neither party shall use any
designation of the other party in any 

  
 17 

	 	
promotional activity associated with this Agreement or the LICENSED TECHNOLOGY. Neither party shall issue any press release or make any public statement in regard to this Agreement without the
prior written approval of the other party, except LICENSEE may make such disclosures as are necessary or appropriate to comply with its obligations under applicable laws, rules and regulations of the Securities and Exchange Commission and securities
exchange upon which LICENSEE’S securities are listed. 

  

	13.4	If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held
illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable. 

 

	13.5	Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party’s right thereafter to demand compliance therewith or with any other provision. Waiver of any default
shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly authorized officer of the party making such waiver. 

 

	13.6	LICENSEE acknowledges that UNIVERSITY is free to publish the results of the research activities of its faculty, staff and students, even though such publication may involve the PATENT RIGHTS or LICENSED TECHNOLOGY.
UNIVERSITY agrees to submit to LICENSEE any proposed publication or presentation regarding the subject matter specifically described in the PATENT RIGHTS for prior review by LICENSEE at least [***] days before its submittal for publication or its
presentation. LICENSEE may, within [***] days after receipt of such proposed publication, request that such proposed publication be delayed not more than [***] days in order to allow for protection of intellectual property rights. 

 

	13.7	 The term “Confidential Information” shall mean any and all proprietary or confidential information of UNIVERSITY or LICENSEE which may be
exchanged between parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that either party can establish by competent proof

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 18 

	 	
that it: (i) is publically disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; (ii) was known to the receiving party prior to
the date of this Agreement, which knowledge was acquired independently and not from another party hereto (or such party’s employees); (iii) is subsequently disclosed to the receiving party in good faith by a third party who has a right to
make such disclosure; or (iv) has been published by a third party as a matter of right. The parties agree that during the term of this Agreement, and for a period of [***] years after this Agreement terminates, a party receiving Confidential
Information of the other party will (a) maintain in confidence such Confidential Information; (b) not disclose such Confidential Information to any third party and (c) not use such confidential Information for any purpose except those
permitted in this Agreement. Notwithstanding the foregoing, if a party is required by law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the
minimum required to make such disclosure shall limit the same to the minimum required to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such
disclosure that party shall notify the other party shall notify the other party, not later than ten (10) days (or shorter period of time as may be practicable under the circumstances) before the disclosure in order to allow that other party to
comment and/or to obtain protective or other order, including extensions of time and the like, with respect to such disclosure. In addition, a party may disclose Confidential Information to the other party to employees, to sublicensees and potential
sublicensees (in the case of LICENSEE), or to other third parties in connection with due diligence or similar investigations by third parties or potential third party investors in confidential financing document, provided, in each case, that any
such employee, consultant, agent, sublicense, potential sublicense or other third party agrees in writing to be bound by terms of confidentiality and non-use at least as stringent as those set forth in this Section 13.7. 

 

	13.8	The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult with their legal counsel and/or other advisors with respect to the PATENT RIGHTS, LICENSED TECHNOLOGY, and the terms of
this Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 19 

	13.9	The parties agree that this Agreement constitutes an arm’s length business transaction and does not create a fiduciary relationship. 

 

	13.10	LICENSEE agrees that with respect to the performance of this Agreement or the practice of the rights granted by the UNIVERSITY hereunder, it shall comply with any and all applicable United States export control laws and
regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department’s Office of Foreign Asset Controls. 

  

	13.11	If LICENSEE challenges the validity or enforceability of UNIVERSITY’S PATENT RIGHTS or UNIVERSITY’S ownership of the PATENT RIGHTS anywhere in the world, the LICENSEE shall continue to pay to UNIVERSITY all
royalties and other financial obligations required under this Agreement, to include patent costs and fees. If any such challenge is unsuccessful by LICENSEE, the royalty rates and any non-royalty sublicense income rate set forth in Article 4.1 above
shall automatically double in value, to include all royalty minimums and floors; and LICENSEE shall reimburse UNIVERSITY for all fees and costs associated with defending such action, to include attorneys’ and expert fees. The effective date of
such increase in royalty rates shall be the date of the first court order declaring any claim of the PATENT RIGHTS as valid or enforceable. 

  
 20 

 IN WITNESS WHEREOF, the parties have set their hands and seals as of the date set forth on the
first page hereof. 
  

			
	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
		
	By	 	 /s/ Jerome Cochran

		 	Jerome Cochran
		 	Executive Vice Chancellor
	
	EXAGEN DIAGNOSTICS, INC.
		
	By	 	 /s/ Scott L. Glenn

		 	Scott L. Glenn
		 	President/CEO

  
 21 

 EXHIBIT A 

PATENT RIGHTS 
  

															
	 University
 Case

Number
	  	 Patent Title
	  	 Country
	  	 Application Number
	  	 Filing Date
	  	 Patent Number
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 

EXCLUDED PATENT RIGHTS 
  

															
	 University
 Case

Number
	  	 Patent Title
	  	 Country
	  	 Application Number
	  	 Filing Date
	  	 Patent Number
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]